DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ELIQUIS
» See Plans and Pricing
All Clinical Trials for ELIQUIS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01675076 | Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events | Recruiting | Boehringer Ingelheim | Phase 3 | 2013-01-01 | The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma. |
| NCT01675076 | Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events | Recruiting | Heart and Stroke Foundation of Canada | Phase 3 | 2013-01-01 | The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma. |
| NCT01675076 | Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events | Recruiting | Ottawa Heart Institute Research Corporation | Phase 3 | 2013-01-01 | The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma. |
| NCT01884337 | Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery | Recruiting | Pfizer | Phase 4 | 2015-03-01 | The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement |
| NCT01884337 | Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery | Recruiting | Bristol-Myers Squibb | Phase 4 | 2015-03-01 | The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement |
| NCT01884350 | Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) | Completed | Bristol-Myers Squibb | Phase 4 | 2013-10-01 | The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks |
| NCT01885585 | Eliquis Regulatory Post Marketing Surveillance (rPMS) | Completed | Bristol-Myers Squibb | N/A | 2014-07-01 | The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ELIQUIS
Condition Name
Clinical Trial Locations for ELIQUIS
Trials by Country
Clinical Trial Progress for ELIQUIS
Clinical Trial Phase
Clinical Trial Sponsors for ELIQUIS
Sponsor Name
